JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

JNJ

186.41

-0.19%↓

ABT

124.42

-1.71%↓

TMO

558.41

+0.1%↑

ISRG

537.45

-1.46%↓

DHR

213.99

-1.31%↓

Home・Aandelen Lijst・Arbutus Biopharma Corp

Arbutus Biopharma Corp

Gesloten

4.61 0.66

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

4.47

Max

4.75

Belangrijke statistieken
By Trading Economics
Inkomsten	27M 2.5M
Verkoop	9M 11M
Winstmarge	23.494
Werknemers	44
EBITDA	27M 2.6M

Marktinformatie
By TradingEconomics
Marktkapitalisatie	217M 857M
Vorige openingsprijs	3.95
Vorige sluitingsprijs	4.61

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

3.255 / 3.365 Steun & Weerstand

Arbutus Biopharma Corp Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

29 okt 2025, 23:28 UTC

Populaire aandelen

Stocks to Watch: Chipotle, Align, Sprouts Farmers Market, Meta

29 okt 2025, 23:07 UTC

Winsten

Prudential PLC 3Q New Business Profit Up 13%

30 okt 2025, 00:00 UTC

Winsten

The Hamptons Luxury Housing Market Is Staging a Comeback for the Ages -- WSJ

30 okt 2025, 00:00 UTC

Winsten

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

30 okt 2025, 00:00 UTC

Winsten

Renesas Electronics 9-Mos Loss Y69.09B Vs Net Y197.30B

29 okt 2025, 23:46 UTC

Marktinformatie

Nikkei May Decline Amid Caution Ahead of BOJ Decision -- Market Talk

29 okt 2025, 23:40 UTC

Winsten

Meta Shares Fall on Accelerating AI Spending Despite Record Revenue -- WSJ

29 okt 2025, 23:38 UTC

Marktinformatie

Gold Rises on Possible Dip-Buying After Falling on Powell's Remarks -- Market Talk

29 okt 2025, 23:25 UTC

Winsten

Alphabet Stock Jumps on Big Earnings Beat -- Barrons.com

29 okt 2025, 22:51 UTC

Winsten

Google Revenue Soars as AI Boom Lifts Cloud Business -- 2nd Update

29 okt 2025, 22:45 UTC

Winsten

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 6th Update

29 okt 2025, 22:41 UTC

Winsten

Prudential PLC 3Q New Business Profit Up 13% on Year to $705.0M >2378.HK

29 okt 2025, 22:41 UTC

Winsten

Prudential PLC APE Sales Up 10% on Year, to $1.72B >2378.HK

29 okt 2025, 22:09 UTC

Winsten

Microsoft Reports Strong Earning as Azure Cloud Revenue Soars by 40%. The Stock Is Still Down. -- Barrons.com

29 okt 2025, 22:08 UTC

Marktinformatie

Winsten

Starbucks Revamps Stores in Pursuit of 'Warm' Atmosphere -- Market Talk

29 okt 2025, 21:58 UTC

Winsten

Alphabet Continues to Allocate More Resources to Waymo, CFO Says

29 okt 2025, 21:58 UTC

Winsten

Alphabet's Google Cloud Backlog Rose on Strong Demand for Enterprise AI, CFO Says

29 okt 2025, 21:57 UTC

Winsten

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 5th Update

29 okt 2025, 21:54 UTC

Winsten

Meta's Margins Are Slipping As AI Costs Mount. The Stock Is Falling. -- Barrons.com

29 okt 2025, 21:46 UTC

Winsten

Alphabet CEO Sees Strong Growth and Momentum for Waymo Continuing in 2026

29 okt 2025, 21:43 UTC

Winsten

Alphabet's Google Cloud Signing Larger Deals, Deepening Relationships With Existing Customers, CEO Says

29 okt 2025, 21:43 UTC

Winsten

Alphabet CEO: More Than 70% of Existing Google Cloud Customers Use AI Products

29 okt 2025, 21:42 UTC

Winsten

IGO 1Q Nova Cash Cost A$6.84/Pound, Up 72% On-Quarter

29 okt 2025, 21:42 UTC

Winsten

IGO 1Q Nova Copper Output 1,377 Tons, Down 41% On-Quarter

29 okt 2025, 21:41 UTC

Winsten

IGO 1Q Nova Nickel Sales 3,320 Tons, Down 5% On-Quarter

29 okt 2025, 21:41 UTC

Winsten

Microsoft's Cloud Services Power Earnings Beyond Wall Street Expectations -- 4th Update

29 okt 2025, 21:41 UTC

Winsten

Alphabet Signed New Google Cloud Customers Faster in 3Q, CEO Says

29 okt 2025, 21:41 UTC

Winsten

IGO 1Q Nova Nickel Production 3,429 Tons, Down 33% On-Quarter

29 okt 2025, 21:40 UTC

Winsten

IGO: Talks Ongoing With Kwinana JV Partner to Settle on Optimum Pathway For Refinery

29 okt 2025, 21:39 UTC

Winsten

IGO 1Q Kwinana Sustaining, Improvement Capex A$8.3 Million

Peer Vergelijking

Prijswijziging

Arbutus Biopharma Corp Prognose

Beoordelingsconsensus

By TipRanks

0 ratings

Buy

Hold

Sell

Gebaseerd op 0 analisten die aandelenratings hebben gegeven aan Arbutus Biopharma Corp - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

3.255 / 3.365Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arbutus Biopharma Corp

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.